Advancing Pediatric Oncology: Dr. Hunter Jonus Leads Innovative Gamma Delta T Cell Therapy Research for High-Risk Neuroblastoma
admin Dr. Hunter Jonus, a prominent researcher at Emory University’s Department of Pediatrics, has been designated...
admin
GSK Unveils Ambitious $2.5 Billion Restructuring Plan to Navigate Patent Cliff and Fuel Future Growth
London, UK – Pharmaceutical giant GSK has announced a comprehensive, multi-billion-dollar cost-cutting program designed to...
Welcoming Three New Leaders to the CureSearch Board of Directors
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to ending childhood cancer by...
Claris Biotherapeutics Secures $118 Million Series B Funding and Fortifies Leadership for Late-Stage Eye Drug Development
Claris Biotherapeutics, a New Jersey-based biotechnology firm, has announced a significant milestone, successfully closing a...
Turning Grief into Global Action The Legacy of Nathan Gray and the Multi-Center Trial to Cure Relapsed Wilms Tumor
The transition into a new school year is typically marked by the purchase of supplies...
CureSearch Expands Pediatric Oncology Support with 2026 Community Impact Awards Focused on Psychosocial Care and Family Well-Being
The national non-profit organization CureSearch for Children’s Cancer has announced a significant expansion of its...
FDA scientists question Capricor data; Legend CEO steps down
The biopharmaceutical industry experienced a dynamic week marked by significant corporate developments, regulatory challenges, and...
From Diagnosis to the Runway: Valerie’s Journey Through Hodgkin Lymphoma and Her Role as a 2024 Glamorama Ambassador
In the bedroom of ten-year-old Valerie, a piece of artwork serves as a definitive statement...
From Diagnosis to Survivorship The Journey of Amari and the Fight Against Pediatric Wilms Tumor
The journey of pediatric cancer for Amari and her family began with a sudden, harrowing...
Argenx Acquires Forte Biosciences in Landmark $2.2 Billion Deal, Bolstering Immunology Pipeline with CD122-Targeting Antibody
Argenx, the Netherlands-based biopharmaceutical giant, announced on Monday, July 27, 2026, its definitive agreement to...
